Elastin-like polypeptide LCST modulation via thioether alkylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying the lower critical solution temperature (LCST) of recombinant elastin-like polypeptides (ELPs) are complex and require biotechnological approaches, lacking efficient chemical processes that can selectively modify the Xaa residue within the ELP domain.
Innovation Solution
A thioether alkylation process is used to modify the methionine residues in ELPs, allowing for precise and selective chemical modulation of the LCST, enabling the preparation of modified ELPs with altered solubility properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If biotechnological approaches are used to modify the LCST of ELPs, then the modification can be achieved, but the process becomes complex
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the Xaa residue in the ELP repeating unit through systematic variation of hydrophobicity parameters. By changing the side chain properties of the amino acid residue (e.g., using different hydrophobicity values), the LCST can be precisely tuned without complex biotechnological procedures. This involves selecting amino acids with specific hydrophobicity characteristics to achieve desired transition temperatures.
Solution Approach 2:
The patent replaces complex biotechnological approaches with a simpler chemical methodology. Instead of using elaborate genetic engineering or cellular expression systems, the invention employs direct chemical selection and assembly of amino acid sequences with predetermined hydrophobicity properties. This substitution of mechanical/biological complexity with chemical simplicity resolves the contradiction between precision and process complexity.
2Ease of manufacture
If chemical modifications are used to modify ELPs, then the process can be simplified, but selective modification of the Xaa residue is difficult
Solution Approach 1:
The patent applies local quality by designing modifications that specifically target the Xaa residue position within the repeating unit while leaving other positions (Val, Pro, Gly) unchanged. The hydrophobicity modification is localized to the side chain of the Xaa amino acid, allowing selective alteration of this specific residue's properties without affecting the overall ELP structure or other amino acid positions. This enables ease of manufacture with maintained selectivity.
Solution Approach 2:
The patent uses parameter changes to achieve selective modification by varying the hydrophobicity parameter of the Xaa residue specifically. By changing only the side chain hydrophobicity of the Xaa position while maintaining the rest of the repeating unit structure, the method achieves both ease of manufacture and residue-specific selectivity through systematic parameter variation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This chemical process effectively shifts the LCST of ELPs, providing a simpler and more precise method for modulating their solubility properties, which can be applied in drug delivery, protein purification, and other biomedical applications.
Implementation Method 1
A thioether alkylation process is used to modify the methionine residues in ELPs, allowing for precise and selective chemical modulation of the LCST
Implementation Method 2
ELPs exhibit a lower critical solution temperature (LCST), also referred as an inverse temperature transition (Tt), similar to synthetic polymers such as poly(N-isopropylacrylamide) (pNIPAM). ELP chains are fully soluble in water below the LCST, while switching to an insoluble state above the LCST.
Data Source
AI summary
The present invention concerns the use of a thioether alkylation process for modulating the lower critical solution temperature of an elastin-like polypeptide comprising at least one methionine residue. It also concerns derivatives of elastin-like polypeptides and their preparation process.